RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0041-1740208
Analysis of the Role of Female Hormones During Infection by COVID-19
Análise do papel dos hormônios femininos durante a infecção por COVID-19![](https://www.thieme-connect.de/media/10.1055-s-00030576/202112/lookinside/thumbnails/10-1055-s-0041-1740208_200404-1.jpg)
Abstract
Women have metabolic, immunological, and genetic variables that ensure more protection from coronavirus infection. However, the indication of treatment for several pathologies and contraception is determined by hormones that have adverse effects and raise doubts about their use during the COVID-19 pandemic. Therefore, the present study searches women specificities and the relation between female sexual hormones and COVID-19, and reports the main recommendations in this background. To this end, a review of the literature was conducted in the main databases, auxiliary data sources, and official websites. Therefore, considering the hypercoagulability status of COVID-19, the debate about the use of contraceptives due to the relative risk of thromboembolic effects that they impose arises. However, the current available evidence, as well as the recommendations of main health organs around the world, demonstrate that the use of hormonal contraceptives must be maintained during the pandemic.
Resumo
As mulheres possuem variáveis metabólicas, imunológicas e genéticas que conferem maior proteção à infecção pelo coronavírus. Todavia, a indicação de tratamento para certas patologias e para a contracepção é determinada por hormônios que possuem efeitos adversos e levantam dúvidas quanto ao seu uso durante a pandemia da COVID-19. Desta forma, o presente estudo busca investigar as especificidades da mulher e a relação dos hormônios sexuais femininos com a COVID-19, assim como relatar as principais recomendações neste contexto. Para isso, realizou-se uma revisão da literatura nas principais bases de dados, fontes auxiliares de dados e sites oficiais. Portanto, considerando o estado hipercoagulável da COVID-19, surge o debate quanto à utilização de contraceptivos pelo seu risco relativo de efeitos tromboembólicos. No entanto, as atuais evidências disponíveis, assim como as recomendações dos principais órgãos de saúde do mundo, demonstraram que o uso de contraceptivos hormonais deve ser mantido durante a pandemia.
Publikationsverlauf
Eingereicht: 12. Oktober 2020
Angenommen: 31. August 2021
Artikel online veröffentlicht:
21. Dezember 2021
© 2021. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 World Health Organization. Coronavirus disease (COVID-19) outbreak situation [Internet]. 2020 [cited 2020 Sep 10]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
- 2 Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7 (06) e438-e440 DOI: 10.1016/S2352-3026(20)3014(20)30145-9.
- 3 Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol 2020; 20 (07) 442-447 DOI: 10.1038/s41577-020-0348-8.
- 4 Weinberger M, Hayes B, White J, Skibiak J. Doing things differently: what it would take to ensure continued access to contraception during COVID-19. Glob Health Sci Pract 2020; 8 (02) 169-175 DOI: 10.9745/GHSP-D-20-00171.
- 5 Suba Z. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients. J Pharm Pharm Sci 2020; 23 (01) 75-85 DOI: 10.18433/jpps31069.
- 6 Strope JD, Chau CH, Figg WD. Are sex discordant outcomes in COVID-19 related to sex hormones?. Semin Oncol 2020; 47 (05) 335-340 DOI: 10.1053/j.seminoncol.2020.06.002.
- 7 Grandi G, Facchinetti F, Bitzer J. The gendered impact of coronavirus disease (COVID-19): do estrogens play a role?. Eur J Contracept Reprod Health Care 2020; 25 (03) 233-234 DOI: 10.1080/13625187.2020.1766017.
- 8 Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol 2017; 198 (10) 4046-4053 DOI: 10.4049/jimmunol.1601896.
- 9 Breithaupt-Faloppa AC, Correia CJ, Prado CM, Stilhano RS, Ureshino RP, Moreira LFP. 17β-Estradiol, a potential ally to alleviate SARS-CoV-2 infection. Clinics (São Paulo) 2020; 75: e1980 DOI: 10.6061/clinics/2020/e1980.
- 10 Li Y, Jerkic M, Slutsky AS, Zhang H. Molecular mechanisms of sex bias differences in COVID-19 mortality. Crit Care 2020; 24 (01) 405 DOI: 10.1186/s13054-020-03118-8.
- 11 Rozenberg S, Vandromme J, Martin C. Are we equal in adversity? Does Covid-19 affect women and men differently?. Maturitas 2020; 138: 62-68 DOI: 10.1016/j.maturitas.2020.05.009.
- 12 Bonan C, Teixeira LA, Nakano AR. Absorção e metabolização dos hormônios sexuais e sua transformação em tecnologias contraceptivas: percursos do pensamento médico no Brasil. Ciênc Saúde Coletiva. 2017; 22 (01) 107-16 DOI: 10.1590/1413-81232017221.26532016.
- 13 Stelzig KE, Canepa-Escaro F, Schiliro M, Berdnikovs S, Prakash YS, Chiarella SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2020; 318 (06) L1280-L1281 DOI: 10.1152/ajplung.00153.2020.
- 14 Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16 (10) 626-638 DOI: 10.1038/nri.2016.90.
- 15 Zeng F, Dai C, Cai P, Wang J, Xu L, Li J. et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex. J Med Virol 2020; 92 (10) 2050-2054 DOI: 10.1002/jmv.25989.
- 16 Di Stadio A, Della Volpe A, Ralli M, Ricci G. Gender differences in COVID-19 infection. The estrogen effect on upper and lower airways. Can it help to figure out a treatment?. Eur Rev Med Pharmacol Sci 2020; 24 (10) 5195-5196 DOI: 10.26355/eurrev_202005_21298.
- 17 Cutolo M, Smith V, Paolino S. Understanding immune effects of oestrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination. Clin Exp Rheumatol 2020; 38 (03) 383-386
- 18 Nachman S. Estrogen patch for COVID-19 symptoms [Internet]. New York: Stony Brook University; 2020 [cited 2020 Sep 15]. NCT04359329. Available from: https://clinicaltrials.gov/ct2/show/NCT04359329
- 19 Ghandehari S. Progesterone for the treatment of COVID-19 in hospitalized men [Internet]. Los Angeles: Cedars Sinai Medical Center; 2020 [cited 2020 Sep 15]. NCT04365127. Available from: https://clinicaltrials.gov/ct2/show/NCT04365127
- 20 Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med 2020; 202 (05) 756-759 DOI: 10.1164/rccm.202001-0179LE.
- 21 Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK. et al. Covid-19 in critically Ill patients in the Seattle Region - Case series. N Engl J Med 2020; 382 (21) 2012-2022 DOI: 10.1056/NEJMoa2004500.
- 22 Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147 DOI: 10.1016/j.thromres.2020.04.013.
- 23 Fabregues F, Peñarrubia J. Assisted reproduction and thromboembolic risk in the COVID-19 pandemic. Reprod Biomed Online 2020; 41 (03) 361-364 DOI: 10.1016/j.rbmo.2020.06.013.
- 24 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX. et al; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720 DOI: 10.1056/NEJMoa2002032.
- 25 Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P. et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020; 20 (10) 1135-1140 DOI: 10.1016/S1473-3099(20)30434-5.
- 26 Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020; 220: 1-13 DOI: 10.1016/j.trsl.2020.04.007.
- 27 Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N. et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 2020; 77 (02) 198-209 DOI: 10.1111/his.14134.
- 28 Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pão CRR. et al. Platelet activation and platelet-monocyte aggregates formation trigger tissue factor expression in severe COVID-19 patients. Blood 2020; 136 (11) 1330-1341 DOI: 10.1182/blood.2020007252.
- 29 Vlachodimitropoulou Koumoutsea E, Vivanti AJ, Shehata N, Benachi A, Le Gouez A, Desconclois C. et al. COVID-19 and acute coagulopathy in pregnancy. J Thromb Haemost 2020; 18 (07) 1648-1652 DOI: 10.1111/jth.14856.
- 30 International Federation of Gynecology and Obstetrics (FIGO). COVID-19 contraception and family planning [Internet]. 2020 [cited 2020 Jul 12]. Available from: https://www.figo.org/covid-19-contraception-family-planning
- 31 World Health Organization. Anticoncepção / Planejamento familiar e COVID-19 [Internet]. 2020 [cited 2020 Jul 15]. Available from: https://www.who.int/reproductivehealth/publications/emergencies/WHO-COVID-Q-and-A-contraception-por.pdf?ua=1
- 32 Federação Brasileira das Associações de Ginecologia e Obstetrícia, Comissão Nacional de Anticoncepção. Anticoncepção durante a pandemia por COVID-19 [Internet]. 2020 [cited 2020 Set 10]. Available from: https://www.febrasgo.org.br/pt/covid19/item/1002-anticoncepcao-durante-a-pandemia-por-covid-19
- 33 Riley T, Sully E, Ahmed Z, Biddlecom A. Estimates of the potential impact of the COVID-19 pandemic on sexual and reproductive health in low- and middle-income countries. Int Perspect Sex Reprod Health 2020; 46: 73-76 DOI: 10.1363/46e9020.
- 34 Faculty of Sexual and Reproductive Healthcare. FSRH CEU clinical advice to support provision of effective contraception during the COVID-19 outbreak [Internet]. 2020 [cited 2020 Set 10]. Available from: https://www.fsrh.org/documents/fsrh-ceu-clinical-advice-to-support-provision-of-effective/
- 35 Ramírez I, De la Viuda E, Baquedano L, Coronado P, Llaneza P, Mendoza N. et al. The thromboembolic risk in covid-19 women under hormonal treatment group. Maturitas 2020; 138: 78-79 DOI: 10.1016/j.maturitas.2020.05.021.
- 36 Cagnacci A, Bonaccorsi G, Gambacciani M. board of the Italian Menopause Society. Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued?. Maturitas 2020; 138: 76-77 DOI: 10.1016/j.maturitas.2020.05.022.
- 37 Rawla P, Pradeep Raj J, Thandra KC, Bandaru SS. Superior mesenteric vein thrombosis in a patient on oral contraceptive pills. Gastroenterol Res 2017; 10 (06) 380-382 DOI: 10.14740/gr903w.
- 38 Sueta D, Akahoshi R, Okamura Y, Kojima S, Ikemoto T, Yamamoto E. et al. Venous Thromboembolism Due to Oral Contraceptive Intake and Spending Nights in a Vehicle -A Case from the 2016 Kumamoto Earthquakes. Intern Med 2017; 56 (04) 409-412 DOI: 10.2169/internalmedicine.56.7785.
- 39 Paschou SA, Goulis DG, Lambrinoudaki I, Papanas N. Menopausal hormone therapy for women with obesity in the era of COVID-19. Case Rep Womens Health 2020; 27: e00233 DOI: 10.1016/j.crwh.2020.e00233.
- 40 Plu-Bureau G, Sabbagh E, Hugon-Rodin J. [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines]. Gynécol Obstét Fertil Sénol 2018; 46 (12) 823-833 DOI: 10.1016/j.gofs.2018.10.007.
- 41 Sitruk-Ware R. Hormonal contraception and thrombosis. Fertil Steril 2016; 106 (06) 1289-1294 DOI: 10.1016/j.fertnstert.2016.08.039.
- 42 Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M. Oral contraceptives and HRT risk of thrombosis. Clin Appl Thromb Hemost 2018; 24 (02) 217-225 DOI: 10.1177/1076029616683802.
- 43 Fruzzetti F, Cagnacci A. Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives?. Open Access J Contracept 2018; 9: 75-79 DOI: 10.2147/OAJC.S179673.
- 44 Rott H. Birth control pills and thrombotic risks: differences of contraception methods with and without estrogen. Hamostaseologie 2019; 39 (01) 42-48 DOI: 10.1055/s-0039-1677806.
- 45 McDaid A, Logette E, Buchillier V, Muriset M, Suchon P, Pache TD. et al. Risk prediction of developing venous thrombosis in combined oral contraceptive users. PLoS One 2017; 12 (07) e0182041 DOI: 10.1371/journal.pone.0182041.
- 46 Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94 (04) 328-339 DOI: 10.1016/j.contraception.2016.06.010.
- 47 Larivée N, Suissa S, Eberg M, Joseph L, Eisenberg MJ, Abenhaim HA. et al. Drospirenone-containing combined oral contraceptives and the risk of arterial thrombosis: a population-based nested case-control study. BJOG 2017; 124 (11) 1672-1679 DOI: 10.1111/1471-0528.14358.
- 48 Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière P-O, Rudant J. et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 2016; 353: i2002 DOI: 10.1136/bmj.i2002.
- 49 Hugon-Rodin J, Horellou MH, Conard J, Gompel A, Plu-Bureau G. Type of combined contraceptives, Factor V Leiden mutation and risk of venous thromboembolism. Thromb Haemost 2018; 118 (05) 922-928 DOI: 10.1055/s-0038-1641152.
- 50 Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2018; 25 (11) 1297-1305 DOI: 10.1097/GME.0000000000001232.
- 51 Dulicek P, Ivanova E, Kostal M, Sadilek P, Beranek M, Zak P. et al. Analysis of risk factors of stroke and venous thromboembolism in females with oral contraceptives use. Clin Appl Thromb Hemost 2018; 24 (05) 797-802 DOI: 10.1177/1076029617727857.
- 52 Liaw PC. Mediators of disseminated intravascular coagulation: molecular mechanisms. Blood 2017; 130 (Suppl. 01) SCI-2 DOI: 10.1182/blood.V130.Suppl_1.SCI-2.SCI-2.
- 53 Mahmood IH, Jaber IM. Effects of hormonal contraceptives on serum glucose, lipid profile and some liver function test. Iraqi J Pharm. 2014; 14 (01) 1-6 DOI: 10.33899/iphr.2019.161187.
- 54 Ministério da Saúde. Secretaria de Atenção Primária à Saúde, Nota Técnica No. 10/2020-COSMU/CGCIVI/DAPES/SAPS/MS. Recomendações para as consultas ambulatoriais de saúde da mulher durante a pandemia da COVID19 [Internet]. 2020 [cited 2020 Jul 21]. Available from: http://docs.bvsalud.org/biblioref/2020/05/1095680/notatecnica102020cosmucgcividapessapsms.pdf